Glenmede Trust’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $673K | Buy |
5,267
+240
| +5% | +$30K | ﹤0.01% | 858 |
|
|
2025
Q4 | $613K | Buy |
+5,027
| New | +$576K | ﹤0.01% | 876 |
|
|
2025
Q1 | $439K | Sell |
5,415
-44
| -0.8% | -$3.93K | ﹤0.01% | 952 |
|
|
2024
Q4 | $492K | Sell |
5,459
-1,434
| -21% | -$139K | ﹤0.01% | 940 |
|
|
2024
Q3 | $681K | Buy |
6,893
+239
| +4% | +$23.5K | ﹤0.01% | 829 |
|
|
2024
Q2 | $617K | Hold |
6,654
| – | – | ﹤0.01% | 829 |
|
|
2024
Q1 | $631K | Hold |
6,654
| – | – | ﹤0.01% | 846 |
|
|
2023
Q4 | $594K | Hold |
6,654
| – | – | ﹤0.01% | 845 |
|
|
2023
Q3 | $486K | Sell |
6,654
-318
| -5% | -$25.4K | ﹤0.01% | 850 |
|
|
2023
Q2 | $531K | Hold |
6,972
| – | – | ﹤0.01% | 808 |
|
|
2023
Q1 | $531K | Buy |
6,972
+10
| +0.1% | +$830 | ﹤0.01% | 811 |
|
|
2022
Q4 | $578K | Hold |
6,962
| – | – | ﹤0.01% | 803 |
|
|
2022
Q3 | $551K | Sell |
6,962
-147
| -2% | -$12.4K | ﹤0.01% | 790 |
|
|
2022
Q2 | $527K | Buy |
7,109
+425
| +6% | +$31.9K | ﹤0.01% | 841 |
|
|
2022
Q1 | $600K | Sell |
6,684
-563
| -8% | -$52K | ﹤0.01% | 841 |
|
|
2021
Q4 | $811K | Sell |
7,247
-373
| -5% | -$45K | ﹤0.01% | 804 |
|
|
2021
Q3 | $957K | Hold |
7,620
| – | – | 0.01% | 715 |
|
|
2021
Q2 | $1.03M | Sell |
7,620
-1,030
| -12% | -$135K | 0.01% | 698 |
|
|
2021
Q1 | $1.17M | Sell |
8,650
-343
| -4% | -$51.4K | 0.01% | 643 |
|
|
2020
Q4 | $1.27M | Buy |
8,993
+56
| +0.6% | +$7.17K | 0.01% | 606 |
|
|
2020
Q3 | $994K | Buy |
8,937
+97
| +1% | +$10.9K | 0.01% | 621 |
|
|
2020
Q2 | $989K | Buy |
8,840
+7,177
| +432% | +$707K | 0.01% | 614 |
|
|
2020
Q1 | $157K | Hold |
1,663
| – | – | ﹤0.01% | 1275 |
|
|
2019
Q4 | $157K | Hold |
1,663
| – | – | ﹤0.01% | 1275 |
|
|
2019
Q3 | $126 | Buy |
1,663
+624
| +60% | +$51.9K | ﹤0.01% | 1322 |
|
|
2019
Q2 | $91 | Hold |
1,039
| – | – | ﹤0.01% | 1436 |
|
|
2019
Q1 | $93 | Hold |
1,039
| – | – | ﹤0.01% | 1439 |
|
|
2018
Q4 | $74 | Buy |
+1,039
| New | +$83.7K | ﹤0.01% | 1437 |
|
|
2018
Q3 | – | Sell |
-309
| Closed | -$29K | – | 1862 |
|
|
2018
Q2 | $29K | Sell |
309
-950
| -75% | -$87.3K | ﹤0.01% | 1611 |
|
|
2018
Q1 | $106K | Hold |
1,259
| – | – | ﹤0.01% | 1376 |
|
|
2017
Q4 | $106K | Buy |
1,259
+96
| +8% | +$8.04K | ﹤0.01% | 1376 |
|
|
2017
Q3 | $100K | Buy |
1,163
+788
| +210% | +$63.2K | ﹤0.01% | 1423 |
|
|
2017
Q2 | $26K | Hold |
375
| – | – | ﹤0.01% | 1835 |
|
|
2017
Q1 | $26K | Buy |
+375
| New | +$25.2K | ﹤0.01% | 1835 |
|
|
2016
Q2 | – | Sell |
-850
| Closed | -$43K | – | 2723 |
|
|
2016
Q1 | $43K | Sell |
850
-510
| -38% | -$26.5K | ﹤0.01% | 1572 |
|
|
2015
Q4 | $95K | Buy |
1,360
+700
| +106% | +$47.7K | ﹤0.01% | 1377 |
|
|
2015
Q3 | $41K | Sell |
660
-300
| -31% | -$23.6K | ﹤0.01% | 1652 |
|
|
2015
Q2 | $80K | Buy |
960
+810
| +540% | +$63K | ﹤0.01% | 1478 |
|
|
2015
Q1 | $11K | Hold |
150
| – | – | ﹤0.01% | 2111 |
|
|
2014
Q4 | $9K | Hold |
150
| – | – | ﹤0.01% | 2232 |
|
|
2014
Q3 | $7K | Hold |
150
| – | – | ﹤0.01% | 2188 |
|
|
2014
Q2 | $7K | Hold |
150
| – | – | ﹤0.01% | 2113 |
|
|
2014
Q1 | $7K | Sell |
150
-3,420
| -96% | -$175K | ﹤0.01% | 2109 |
|
|
2013
Q4 | $154K | Hold |
3,570
| – | – | ﹤0.01% | 1247 |
|
|
2013
Q3 | $152K | Hold |
3,570
| – | – | ﹤0.01% | 1232 |
|
|
2013
Q2 | $123K | Buy |
+3,570
| New | +$125K | ﹤0.01% | 1244 |
|
Other funds holding XBI
Glenmede Trust's XBI Position: Q1 2026 in Review
Glenmede Trust increased its State Street SPDR S&P Biotech ETF (XBI) stake by 4.8% in Q1 2026, buying an estimated $30K and bringing the position to 5,267 shares worth $673K. The position accounts for ﹤0.01% of the portfolio, ranked #858.
Glenmede Trust first reported a position in XBI in Q2 2013 and has held it in 46 quarters since. The position peaked at $1.27M in Q4 2020. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Glenmede Trust held 5,267 shares of State Street SPDR S&P Biotech ETF worth $673K as of Q1 2026.
- Glenmede Trust bought 240 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $30K.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #858 holding.
- Glenmede Trust first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 46 quarters since.
- Glenmede Trust's State Street SPDR S&P Biotech ETF position peaked at $1.27M in Q4 2020.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.